Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning
<p>Abstract</p> <p>Background</p> <p>A major challenge in the application of marrow transplantation as a route to immunological tolerance of a transplanted organ is to achieve hematopoietic stem cell (HSC) engraftment with minimal myelosuppressive treatments.</p>...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-04-01
|
Series: | BMC Immunology |
Online Access: | http://www.biomedcentral.com/1471-2172/7/9 |
id |
doaj-88419693dd4c4dc2894d33d125024cec |
---|---|
record_format |
Article |
spelling |
doaj-88419693dd4c4dc2894d33d125024cec2020-11-25T03:12:12ZengBMCBMC Immunology1471-21722006-04-0171910.1186/1471-2172-7-9Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioningFairchild Paul JDaley StephenGraca LuisCobbold Stephen PWaldmann Herman<p>Abstract</p> <p>Background</p> <p>A major challenge in the application of marrow transplantation as a route to immunological tolerance of a transplanted organ is to achieve hematopoietic stem cell (HSC) engraftment with minimal myelosuppressive treatments.</p> <p>Results</p> <p>We here describe a combined antibody protocol which can achieve long-term engraftment with clinically relevant doses of MHC-mismatched bone marrow, without the need for myelosuppressive drugs. Although not universally applicable in all strains, we achieved reliable engraftment in permissive strains with a two-stage strategy: involving first, treatment with anti-CD8 and anti-CD4 in advance of transplantation; and second, treatment with antibodies targeting CD4, CD8 and CD40L (CD154) at the time of marrow transplantation. Long-term mixed chimerism through co-receptor and co-stimulation blockade facilitated tolerance to donor-type skin grafts, without any evidence of donor-antigen driven regulatory T cells.</p> <p>Conclusion</p> <p>We conclude that antibodies targeting co-receptor and co-stimulatory molecules synergise to enable mixed hematopoietic chimerism and central tolerance, showing that neither cytoreductive conditioning nor 'megadoses' of donor bone marrow are required for donor HSC to engraft in permissive strains.</p> http://www.biomedcentral.com/1471-2172/7/9 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fairchild Paul J Daley Stephen Graca Luis Cobbold Stephen P Waldmann Herman |
spellingShingle |
Fairchild Paul J Daley Stephen Graca Luis Cobbold Stephen P Waldmann Herman Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning BMC Immunology |
author_facet |
Fairchild Paul J Daley Stephen Graca Luis Cobbold Stephen P Waldmann Herman |
author_sort |
Fairchild Paul J |
title |
Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning |
title_short |
Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning |
title_full |
Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning |
title_fullStr |
Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning |
title_full_unstemmed |
Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning |
title_sort |
co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning |
publisher |
BMC |
series |
BMC Immunology |
issn |
1471-2172 |
publishDate |
2006-04-01 |
description |
<p>Abstract</p> <p>Background</p> <p>A major challenge in the application of marrow transplantation as a route to immunological tolerance of a transplanted organ is to achieve hematopoietic stem cell (HSC) engraftment with minimal myelosuppressive treatments.</p> <p>Results</p> <p>We here describe a combined antibody protocol which can achieve long-term engraftment with clinically relevant doses of MHC-mismatched bone marrow, without the need for myelosuppressive drugs. Although not universally applicable in all strains, we achieved reliable engraftment in permissive strains with a two-stage strategy: involving first, treatment with anti-CD8 and anti-CD4 in advance of transplantation; and second, treatment with antibodies targeting CD4, CD8 and CD40L (CD154) at the time of marrow transplantation. Long-term mixed chimerism through co-receptor and co-stimulation blockade facilitated tolerance to donor-type skin grafts, without any evidence of donor-antigen driven regulatory T cells.</p> <p>Conclusion</p> <p>We conclude that antibodies targeting co-receptor and co-stimulatory molecules synergise to enable mixed hematopoietic chimerism and central tolerance, showing that neither cytoreductive conditioning nor 'megadoses' of donor bone marrow are required for donor HSC to engraft in permissive strains.</p> |
url |
http://www.biomedcentral.com/1471-2172/7/9 |
work_keys_str_mv |
AT fairchildpaulj coreceptorandcostimulationblockadeformixedchimerismandtolerancewithoutmyelosuppressiveconditioning AT daleystephen coreceptorandcostimulationblockadeformixedchimerismandtolerancewithoutmyelosuppressiveconditioning AT gracaluis coreceptorandcostimulationblockadeformixedchimerismandtolerancewithoutmyelosuppressiveconditioning AT cobboldstephenp coreceptorandcostimulationblockadeformixedchimerismandtolerancewithoutmyelosuppressiveconditioning AT waldmannherman coreceptorandcostimulationblockadeformixedchimerismandtolerancewithoutmyelosuppressiveconditioning |
_version_ |
1724651043056254976 |